Search Results 391-400 of 23342 for B cell lymphomas

  1. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  2. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

    It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma.

  3. Hematology - Clinical trials

    Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...

  4. Polatuzumab vedotin-piiq (intravenous route) - Side effects & uses - Mayo Clinic

    Polatuzumab vedotin-piiq injection is used together with other cancer medicines (eg, bendamustine, rituximab) to treat diffuse large B-cell lymphoma (DLBCL) ...

  5. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  6. Anaplastic large cell lymphoma - Diagnosis and treatment - Mayo Clinic

    Blood tests can sometimes show whether anaplastic large cell lymphoma cells are present. Blood tests may be used to test for viruses, including HIV, hepatitis B ...

  7. Clinical trials - Oncology (Medical)

    To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), ...

  8. Mantle cell lymphoma - Doctors and departments - Mayo Clinic

    Find out more about the symptoms, diagnosis and treatment of this type of non-Hodgkin lymphoma.

  9. Hematology - Clinical trials

    ... lymphomas as well as the effectiveness of interventions. ... Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T- ...

  10. Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients - Mayo Clinic

    High-grade BCL with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma). Please note ...